Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study

1

Glofitamab is a bispecific antibody effective in treating relapsed or refractory B-cell non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma.
2

The study involved 24 patients with relapsed/refractory B-cell lymphoma, categorized into three treatment groups based on Glofitamab's use.
3

Glofitamab demonstrated controllable safety and durable anti-tumor activity in various treatment scenarios, including after CAR-T therapy failure.
4

Patients received Glofitamab through a step-up dosing regimen, with specific dosages tailored to their treatment group.
5

The study highlights the potential of Glofitamab as a bridging therapy to CAR-T therapy and as a monotherapy for patients not suitable for CAR-T.

Frontiers In Oncology

by Haoran Xu, Fangce Wang, Chenbo Sun, Bing Xiu, Yi Ding, Bin Xue, Aibin Liang, Wenjun Zhang
July 7, 2026

1